Pharmafile Logo
Pharmafocus logo
Advanced Search

melanoma

Showing 15 posts of 82 posts found.

Iovance’s Amtagvi gains FDA accelerated approval for melanoma treatment

February 19, 2024
Medical Communications Iovance, Oncology, accelerated approval, melanoma

Iovance Biotherapeutics has announced that the US Food and Drug Administration (FDA) has approved Amtagvi (lifileucel) suspension for intravenous infusion …

News

Elekta and BMS partner for digital treatment for melanoma

December 19, 2023
Research and Development BMS, Elekta, Oncology, bristol myers squibb, digital treatment, melanoma

Elekta and Bristol Myers Squibb have announced a pilot collaboration in which the companies plan to develop a digital solution …

News

Melanoma market to reach $7.4bn by 2029

April 30, 2021
Medical Communications melanoma

A report from GlobalData, Melanoma – Global Drug Forecast and Market Analysis to 2029, has predicted the melanoma industry will …

News
novartis_outside_1

Novartis’ Tafinlar/Mekinist combo improves five-year relapse-free survival in new Phase 3 data

September 17, 2020
Research and Development Novartis, Tafinlar, mekinist, melanoma

Novartis has unveiled promising new Phase 3 data for its combination of Tafinlar (dabrafenib) with Mekinist (trametinib) in the treatment …

News
five-clear-glass-vial-bottles

Scotland approves targetted combination therapy for advanced melanoma

February 11, 2020
Manufacturing and Production NHS, SMC, Scotland, UK, advanced melanoma, melanoma

The Scottish Medicines Consortium (SMC) has approved targeted combination therapy for the treatment of adult patient with unresectable or metastatic …

News
roche

Roche’s Tecentriq combo boosts progression-free survival in previously untreated BRAF V600 mutation-positive advanced melanoma

December 16, 2019
Manufacturing and Production, Research and Development, Sales and Marketing Roche, melanoma, pharma, tecentriq

Roche has lifted the curtain on new Phase 3 data for its immunotherapy Tecentriq (atezolizumab), confirming that the therapy, when …

News
opdivo_1_1

EMA’s CHMP recommends new dosing schedule for Opdivo in melanoma

September 25, 2019
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, CHMP, EMA, melanoma, opdivo, pharma

Bristol-Myers Squibb has revealed that its blockbuster immunotherapy drug Opdivo (nivolumab) has secured recommendation from the EMA’s Committee for Medicinal …

News
merck-keytruda

MSD’s Keytruda recommended on NHS in Scotland for Stage 3 melanoma

May 14, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, Scotland, Scottish Medicines Consortium, keytruda, melanoma, pharma

MSD has revealed that Keytruda (pembrolizumab) will be made available to NHS Scotland patients after the Scottish Medicines Consortium (SMC) …

News

Living with melanoma after surgery

February 25, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, melanoma, patient experience, pharma

Dr Elizabeth Walmsley was left lost when she received her melanoma diagnosis. Thankfully, through perseverance and the advice of friends …

Feature

Smoking may limit immune system’s ability to fight cancer, study shows

February 18, 2019
Sales and Marketing Cancer, cancer research, immune system, immunology, melanoma, oncology, smoking

Smoking may limit the body’s ability to fight melanoma, according to a study published in the journal Cancer Research. The …

News
imp_pologne2

NICE recommends Pierre Fabre’s Braftovi in BRAF V600-mutated advanced melanoma

January 21, 2019
Sales and Marketing Braftovi, Cancer, NICE, Pierre Fabre, UK, melanoma, pharma

Braftovi (encorafenib), a BRAF kinase inhibitor developed by Pierre Fabre, has been awarded approval in combination with Mektovi (binimetinib) by …

News
opdivo_1_1

Opdivo to be made available to UK melanoma patients via the Cancer Drugs Fund

November 30, 2018
Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, NICE, UK, melanoma, pharma

Bristol-Myers Squibb’s blockbuster immunotherapy Opdivo (nivolumab) is set to be made available to patients in the UK via the Cancer …

News

MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund

November 19, 2018
Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma

MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …

News

BMS’ Opdivo and Yervoy combination shows outstanding survival rate in cancer patients

October 22, 2018
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Yervoy, melanoma, opdivo

American pharma firm Bristol-Myers Squibb have announced that more than 53% of patients with advanced melanoma, who were treated with …

News

NICE recommends Novartis combo as first-ever BRAF-targeted therapy for advanced post-surgery melanoma

September 17, 2018
Sales and Marketing Cancer, NICE, Novartis, Tafinlar, mekinist, melanoma, pharma

NICE has taken the decision to recommend the first ever first BRAF-targeted therapy for use on the NHS in England …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024